Evidence map›Paper›PMID 40846792›Full record

ReviewEuropean journal of human genetics : EJHG2025

Genomic sequencing technologies for rare disease in mainstream healthcare: the current state of implementation.

Michael P Mackley, Pankaj B Agrawal, Sara S Ali, Alison D Archibald, Belinda Dawson-McClaren, Holly Ellard, Lucinda Freeman, Yuanyuan Gu, Kushani Jayasinghe, Shan Jiang and 8 more

Abstract readReview
In one paragraph

Review in European journal of human genetics : EJHG, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Mainstreaming genomic testing for mitochondrial disease in Australia.European journal of human genetics : EJHG · 2026
    Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Insights in genetics: from molecular mechanisms to patient perspectives.European journal of human genetics : EJHG · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Michael P MackleyDivision of Clinical & Metabolic Genetics, Department of Paediatrics, The Hospital for Sick Children, Toronto, ON, Canada. michael.mackley@mail.utoronto.ca.ORCID 0000-0002-7388-0905
Pankaj B AgrawalDivision of Neonatology, Department of Pediatrics, University of Miami Miller School of Medicine and Holtz Children's Hospital, Jackson Health System, Miami, FL, USA.ORCID 0000-0003-3255-0456
Sara S AliDivision of Neonatology, Department of Pediatrics, University of Miami Miller School of Medicine and Holtz Children's Hospital, Jackson Health System, Miami, FL, USA.
Alison D ArchibaldGenomics in Society, Murdoch Children's Research Institute, Melbourne, VIC, Australia.ORCID 0000-0002-4496-8262
Belinda Dawson-McClarenGenomics in Society, Murdoch Children's Research Institute, Melbourne, VIC, Australia.ORCID 0000-0002-1372-8258
Holly EllardPopulation, Policy and Practice Department, UCL GOS Institute of Child Health, London, UK.ORCID 0009-0004-5345-0192
Lucinda FreemanGraduate School of Health, Faculty of Health, University of Technology Sydney, Sydney, NSW, Australia.ORCID 0000-0002-5814-3894
Yuanyuan GuMacquarie University Centre for the Health Economy, Macquarie Business School and Australian Institute of Health Innovation, Macquarie University, Sydney, NSW, Australia.
Kushani JayasingheDepartment of Nephrology, Monash Health, Melbourne, VIC, Australia.
Shan JiangMacquarie University Centre for the Health Economy, Macquarie Business School and Australian Institute of Health Innovation, Macquarie University, Sydney, NSW, Australia.
Edwin P KirkSchool of Clinical Medicine, University of New South Wales, Sydney, NSW, Australia.ORCID 0000-0002-4662-0024
Celine LewisPopulation, Policy and Practice Department, UCL GOS Institute of Child Health, London, UK.ORCID 0000-0001-7169-1521
Alison McEwenMacquarie University Centre for the Health Economy, Macquarie Business School and Australian Institute of Health Innovation, Macquarie University, Sydney, NSW, Australia.ORCID 0000-0001-8705-1190
Amy NisselleGenomics in Society, Murdoch Children's Research Institute, Melbourne, VIC, Australia.ORCID 0000-0002-8908-5906
Catherine QuinlanDepartment of Paediatrics, The University of Melbourne, Melbourne, VIC, Australia.
Bronwyn TerrillGenomics in Society, Murdoch Children's Research Institute, Melbourne, VIC, Australia.
Erin TuttyGenomics in Society, Murdoch Children's Research Institute, Melbourne, VIC, Australia.
Alisdair McNeillDivision of Neuroscience and Neuroscience Institute, The University of Sheffield, Sheffield, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Genomic sequencing technologies, which include both exome and genome sequencing, as well as panels or targeted analyses using genome-wide approaches, are being implemented across healthcare. Implementation, however, varies greatly by application and jurisdiction, with a diversity of approaches being employed around the world. This review aims to summarise the current state of implementation of genomic testing in mainstream healthcare for the detection of rare disease throughout the lifespan. Through a discussion of evidence gathered to date, highlighting exemplar studies, the following applications of genomic testing will be covered: (1) routine diagnostic genomic testing in the clinic; (2) rapid diagnostic genomic testing in the intensive care unit; (3) genomic newborn screening; and, (4) reproductive genetic carrier screening. Mainstream implementation necessarily extends beyond the clinical genetics service, where genomic testing has historically been offered. Given that the involvement of non-genetics clinicians in the delivery of these technologies has important implications for models of care and education, related areas of growing evidence are also discussed: (5) genetic counsellors working outside clinical genetics services; and, (6) workforce development considerations for mainstream genomics. The diversity of approaches and examples illustrates that integration of genomic technologies into mainstream healthcare is complex and requires significant health system transformation. Efforts to evaluate services, guided by implementation science, will be essential to ensure lessons are shared across jurisdictions and benefit is delivered to patients and the system at-large.

Indexed as

Genetic TestingGenomicsRare DiseasesDelivery of Health CareGenetic CounselingHumansInfant, NewbornNeonatal Screening

Identifiers

PMID40846792
PMCPMC12583809

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.